Open AccessDynamics of neurospecific enolase as a leading marker in determining the functional state of the blood-brain barrier in patients with metabolic coma
Author(s) -
M. O. Deyneko
Publication year - 2020
Publication title -
vìsnik vìnnicʹkogo nacìonalʹnogo medičnogo unìversitetu
Language(s) - English
Resource type - Journals
eISSN - 2522-9354
pISSN - 1817-7883
DOI - 10.31393/reports-vnmedical-2020-24(4)-19
Subject(s) - coma (optics) , enolase , intensive care unit , medicine , intensive care , anesthesia , gastroenterology , intensive care medicine , physics , immunohistochemistry , optics
Annotation. Determining the pathogenetic mechanism of disturbance of consciousness, coma, at the stage of admission of the patient to the intensive care unit is an important point in determining the features of the algorithm of treatment of such patients. The aim of this study was to determine the mechanisms of the primary cause of loss of consciousness (coma) in the acute period of its course and to assess the effectiveness of pathogenetically sound intensive care since the patient's admission to the clinic. We examined 60 patients with coma of neurotropic metabolic (secondary) origin, who were additionally prescribed substances with antioxidant, vasoprotective and energy-protective effects in the algorithm of intensive care. Mean normal values of neurospecific enolase levels were obtained in 20 volunteers. The functional state of the blood-brain barrier was determined on the 1st, 3rd and 10th day of treatment. Ceruloplasmin solution and D-fructose-1,6-diphosphate sodium salt were found to be pathogenetically significant in determining the effects of treatment in patients with metabolic coma.